Form 8-K - Current report:
SEC Accession No. 0001683168-20-004454
Filing Date
2020-12-28
Accepted
2020-12-28 16:30:17
Documents
5
Period of Report
2020-12-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K cns_8k.htm 8-K 22731
2 UNDERWRITING AGREEMENT cns_8k-ex0101.htm EX-1.1 271390
3 FORM OF COMMON STOCK PURCHASE WARRANT cns_8k-ex0401.htm EX-4.1 103837
4 PRESS RELEASE cns_ex9901.htm EX-99.1 8111
5 GRAPHIC image_001.jpg GRAPHIC 5278
  Complete submission text file 0001683168-20-004454.txt   414653
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 201418659
SIC: 2834 Pharmaceutical Preparations